|ATC code||J05AF04 (WHO)|
|Metabolism||Renal elimination (~40%)|
|Biological half-life||0.8–1.5 hours (in adults)|
|Chemical and physical data|
|Molar mass||224.213 g/mol|
|3D model (Jmol)||Interactive image|
Stavudine (d4T), sold under the brand name Zerit among others, is an antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use with other antiretrovirals. It may be used for prevention after a needlestick injury or other potential exposure. It; however, is not a first line treatment. It is given by mouth.
Common side effects include headache, diarrhea, vomiting, rash, and peripheral nerve problems. Severe side effects include high blood lactate, pancreatitis, and an enlarged liver. It is not generally recommended in pregnancy. Stavudine is in the nucleoside analog reverse-transcriptase inhibitor (NRTI) class of medication.
Stavudine was first described in 1966 and approved for use in the United States in 1994. It is on the World Health Organization's List of Essential Medicines, the most important medication needed in a basic health system. It is avaliable as a generic medication. The wholesale cost in the developing world is 1.86 to 5.40 USD per month. The World Health Organization recommends that its use be decreased due to side effects.
Stavudine is used in the treatment of HIV-1 infection, but is not a cure. It is not normally recommended as initial treatment. Stavudine can also reduce your risk of developing HIV-1 infection after coming into contact with the virus either at work (e.g., needlestick) or exposure to infected blood or other bodily fluids. It is always used in combination with other HIV medications for the better control of the infection and a reduction in HIV complications.
The World Health Organization (WHO) recommends stavudine to be phased out to due to its high toxicity levels. If the drug must be used, it is recommended to use low dosages to reduce the occurrence of side effects; however, a 2015 Cochrane review found no clear advantage between high and low dosage regimens.
Pregnancy and breastfeeding
Stavudine has been demonstrated to affect the fetus in animals studies but no data is available from human studies. Pregnant women should therefore be given stavudine only if the potential benefits outweight the potential harm to the fetus. Additionally, there have been case reports of fatal lactic acidosis in pregnant women receiving combination therapy of stavudine and didanosine with other antiviral agents.
The Centers for Disease Control and Prevention recommend that HIV-infected mothers not to breastfeed their infants, in order to avoid the risk of HIV transmission through breast milk. There is also evidence that stavudine does get into animal breast milk, although no data is available for human breast milk.
Stavudine is safe for use in children infected with HIV from birth through adolescence. Adverse effects and safety profile are the same as adults.
There is currently no data available for stavudine use in HIV-infected adults aged 65 years or older. However, among 12,000 people over the age of 65, 30% developed peripheral neuropathy. Additionally, since the elderly are more likely to have decreased renal function, they are more likely to develop toxic side effects.
Common side effects
Severe side effects
- Peripheral neuropathy
- Lactic acidosis
- Hepatomegaly with steatosis
- Lipoatrophy/lipodystrophy (fat redistribution/accumulation)
Individuals are monitored for the development of these serious adverse effects. The development of peripheral neuropathy is shown to be dose related, and may be resolved if the drug is discontinued. Individuals with advanced HIV-1 disease, a history of peripheral neuropathy, or individuals on other drugs that have association with neuropathy develop this side effect more often.
Stavudine has been shown in laboratory test to be genotoxic, but with clinical doses its carcinogenic effects are non-existent. Hyperlactatemia, bone mineral density (BMD) loss, reduction in limb fat and an increase in triglycerides were found when administered in high dosages. It is also one of the most likely antiviral drugs to cause lipodystrophy, and for this reason it is no longer considered an appropriate treatment for most patients in developed countries.
HLA-B*4001 may be used as a genetic marker to predict which patients will develop stavudine-associated lipodystrophy, to avoid or shorten the duration of stavudine according to a study in Thailand.
It is still used as first choice in first line therapy in resource poor settings such as in India. Only in case of development of peripheral neuropathy or pregnancy is it changed to the next choice, zidovudine. Safety and effectiveness of dosage titration was not reported in treatment naive patients. It was only reported in those patients with sustained virologic suppression. These findings are not generalized to Stavudine used in ART naive patients who have high viral loads.
On Monday 30 November 2009, the World Health Organization stated that "[The WHO] recommends that countries phase out the use of Stavudine, or d4T, because of its long-term, irreversible side-effects. Stavudine is still widely used in first-line therapy in developing countries due to its low cost and widespread availability. Zidovudine (AZT) or tenofovir (TDF) are recommended as less toxic and equally effective alternatives."
Mechanism of action
Stavudine is a nucleoside analog of thymidine. It is phosphorylated by cellular kinases into an active triphosphate. Stavudine triphosphate inhibits HIV’s reverse transcriptase by competing with the natural substrate, thymidine triphosphate. Reverse transcriptase is the enzyme the virus uses to make a DNA copy of its RNA in order to insert its genetic material into the host’s DNA. Upon incorporation into the DNA strand, stavudine triphosphate causes termination of DNA replication.
Absorption: Stavudine has rapid absorption and good oral bioavailability (F = 0.86).
Distribution: Stavudine does not bind to proteins in the blood.
Elimination: Stavudine is mostly eliminated in the urine and mostly in its unchanged form.
Stavudine is not protein-bound nor does it inhibit the major cytochrome P450 isoforms. Thus, significant drug interactions with drugs metabolized through these pathways or drugs that are protein-bound are unlikely.
Stavudine was first created by Jerome Horwitz in the 1960s and was originally named D4T. When the AIDS epidemic occurred in the 1980s, William Prusoff and Dr. Tai-Shun Lin discovered the anti-HIV properties of Stavudine. The pharmaceutical company Bristol-Myers Squibb manufactures the drug under the trade name Zerit.
It is also the first drug to be granted parallel track status in 1992 by the US Food and Drug Administration (FDA), which allowed for the agency to make Stavudine available to patients before being approved. Stavudine was submitted under the FDA’s accelerated approval process. Through this process, Stavudine’s effectiveness was measured by its effect on the surrogate marker, CD4, instead of clinical endpoints. The FDA concluded that an increase in CD4 cell counts was an indicator of how effective the drug would be against AIDS and HIV infection. Stavudine was the fourth drug to be approved for the treatment of AIDS and HIV infection by the FDA on June 27, 1994. Even after approval, studies were continued to evaluate the clinical benefit of the drug. If there is no indication of clinical benefits, the accelerated approval may be withdrawn.
- "Stavudine Monograph for Professionals - Drugs.com". www.drugs.com. Retrieved 2016-11-09.
- Fischer, Janos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 505. ISBN 9783527607495.
- "WHO Model Lists of Essential Medicines 19th" (PDF). World Health Organization. Retrieved 2016-11-09.
- "Stavudine". International Drug Price Indicator Guide. Retrieved 30 November 2016.
- Magula, N; Dedicoat, M (28 January 2015). "Low dose versus high dose stavudine for treating people with HIV infection.". The Cochrane database of systematic reviews. 1: CD007497. doi:10.1002/14651858.CD007497.pub2. PMID 25627012.
- "Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV—United States, 2016" (PDF). Center for Disease Control and Prevention. Annals of Emergency Medicine. Retrieved 11/08/2016. Check date values in:
- "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents" (PDF). Panel on Antiretroviral Guidelines for Adults and Adolescents, US Department of Health and Human Services (HHS). Retrieved 11/08/2016. Check date values in:
- Bristol-Myers Squibb (December 2012). "Zerit (stavudine) capsules and powder for oral solution prescribing information" (PDF). Princeton, NJ.
- "Stavudine FDA access" (PDF).
- "Pregnant Women, Infants, and Children | Gender | HIV by Group | HIV/AIDS | CDC". www.cdc.gov. Retrieved 2016-11-15.
- "FDA Guideline for Industry: Geriatric Population" (PDF).
- Wangsomboonsiri W, Mahasirimongkol S, Chantarangsu S, et al. (February 15, 2010). "Association between HLA-B*4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen". Clinical Infectious Diseases. 50 (4): 597–604. doi:10.1086/650003. PMID 20073992.
- "New HIV recommendations to improve health, reduce infections and save lives". World Health Organization. November 30, 2009.
- "Jerome Horwitz". Telegraph.co.uk. Retrieved 2016-11-06.
- Prusoff, William (2001-03-19). "The Scientist's Story". The New York Times. ISSN 0362-4331. Retrieved 2016-11-06.
- "FDA Approval of Stavudine (d4T) | News | AIDSinfo". AIDSinfo. Retrieved 2016-11-06.